Anika Therapeutics (ANIK) Competitors $11.31 -0.24 (-2.08%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$11.31 0.00 (0.00%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ANIK vs. CERS, OSUR, UTMD, WST, COO, ALGN, MMSI, HAE, ICUI, and XRAYShould you be buying Anika Therapeutics stock or one of its competitors? The main competitors of Anika Therapeutics include Cerus (CERS), OraSure Technologies (OSUR), Utah Medical Products (UTMD), West Pharmaceutical Services (WST), Cooper Companies (COO), Align Technology (ALGN), Merit Medical Systems (MMSI), Haemonetics (HAE), ICU Medical (ICUI), and DENTSPLY SIRONA (XRAY). These companies are all part of the "health care supplies" industry. Anika Therapeutics vs. Its Competitors Cerus OraSure Technologies Utah Medical Products West Pharmaceutical Services Cooper Companies Align Technology Merit Medical Systems Haemonetics ICU Medical DENTSPLY SIRONA Cerus (NASDAQ:CERS) and Anika Therapeutics (NASDAQ:ANIK) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, media sentiment, community ranking, profitability, earnings, dividends and risk. Do analysts prefer CERS or ANIK? Cerus currently has a consensus target price of $3.50, suggesting a potential upside of 146.48%. Anika Therapeutics has a consensus target price of $20.00, suggesting a potential upside of 76.83%. Given Cerus' higher possible upside, analysts plainly believe Cerus is more favorable than Anika Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cerus 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Anika Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Which has more risk and volatility, CERS or ANIK? Cerus has a beta of 1.55, indicating that its stock price is 55% more volatile than the S&P 500. Comparatively, Anika Therapeutics has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500. Which has preferable earnings & valuation, CERS or ANIK? Cerus has higher revenue and earnings than Anika Therapeutics. Cerus is trading at a lower price-to-earnings ratio than Anika Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCerus$185.14M1.47-$37.49M-$0.10-14.20Anika Therapeutics$117.05M1.39-$82.67M-$3.88-2.91 Does the MarketBeat Community prefer CERS or ANIK? Cerus received 262 more outperform votes than Anika Therapeutics when rated by MarketBeat users. Likewise, 72.34% of users gave Cerus an outperform vote while only 64.57% of users gave Anika Therapeutics an outperform vote. CompanyUnderperformOutperformCerusOutperform Votes57072.34% Underperform Votes21827.66% Anika TherapeuticsOutperform Votes30864.57% Underperform Votes16935.43% Is CERS or ANIK more profitable? Cerus has a net margin of -11.60% compared to Anika Therapeutics' net margin of -59.40%. Anika Therapeutics' return on equity of -2.22% beat Cerus' return on equity.Company Net Margins Return on Equity Return on Assets Cerus-11.60% -40.55% -11.12% Anika Therapeutics -59.40%-2.22%-1.75% Do insiders and institutionals believe in CERS or ANIK? 78.4% of Cerus shares are held by institutional investors. Comparatively, 91.5% of Anika Therapeutics shares are held by institutional investors. 5.6% of Cerus shares are held by company insiders. Comparatively, 9.6% of Anika Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the media prefer CERS or ANIK? In the previous week, Cerus had 7 more articles in the media than Anika Therapeutics. MarketBeat recorded 9 mentions for Cerus and 2 mentions for Anika Therapeutics. Cerus' average media sentiment score of 1.27 beat Anika Therapeutics' score of 0.93 indicating that Cerus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cerus 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Anika Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryCerus beats Anika Therapeutics on 12 of the 19 factors compared between the two stocks. Get Anika Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ANIK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ANIK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANIK vs. The Competition Export to ExcelMetricAnika TherapeuticsSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$162.20M$4.41B$5.57B$8.62BDividend YieldN/A42.67%5.28%4.18%P/E Ratio-1.7028.4427.1720.06Price / Sales1.3971.85409.72157.10Price / Cash3.5351.0838.2534.64Price / Book0.785.917.064.70Net Income-$82.67M$67.63M$3.23B$247.88M7 Day Performance1.07%2.35%2.89%2.66%1 Month Performance-4.56%17.24%9.06%6.40%1 Year Performance-56.67%19.59%31.40%14.07% Anika Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANIKAnika Therapeutics4.227 of 5 stars$11.31-2.1%$20.00+76.8%-56.3%$162.20M$117.05M-1.70300CERSCerus2.6048 of 5 stars$1.32+3.9%$3.50+165.2%-19.3%$252.33M$185.14M-12.00290News CoveragePositive NewsAnalyst RevisionGap UpOSUROraSure Technologies3.2898 of 5 stars$2.85-1.0%$3.00+5.3%-35.1%$213.18M$161.63M19.00840Positive NewsUTMDUtah Medical Products2.5593 of 5 stars$54.73-0.6%N/A-15.6%$177.76M$39.27M13.86180Positive NewsDividend AnnouncementWSTWest Pharmaceutical Services4.7705 of 5 stars$209.43-0.7%$332.50+58.8%-31.7%$15.05B$2.90B31.3010,700Trending NewsCOOCooper Companies3.3999 of 5 stars$67.00-1.9%$100.38+49.8%-23.8%$13.40B$3.93B34.3614,000High Trading VolumeALGNAlign Technology4.7185 of 5 stars$178.51-1.3%$241.25+35.1%-26.8%$12.94B$3.98B31.8223,200Positive NewsMMSIMerit Medical Systems4.1784 of 5 stars$93.64-1.5%$109.11+16.5%+14.5%$5.53B$1.39B45.906,850Positive NewsHAEHaemonetics3.8907 of 5 stars$68.78+1.6%$97.89+42.3%-14.2%$3.30B$1.36B27.082,820Analyst RevisionICUIICU Medical4.5264 of 5 stars$130.54-3.2%$192.67+47.6%+19.6%$3.21B$2.42B-28.5614,500Positive NewsXRAYDENTSPLY SIRONA4.6998 of 5 stars$15.62-2.3%$20.36+30.4%-40.2%$3.11B$3.72B-7.5515,000 Related Companies and Tools Related Companies Cerus Alternatives OraSure Technologies Alternatives Utah Medical Products Alternatives West Pharmaceutical Services Alternatives Cooper Companies Alternatives Align Technology Alternatives Merit Medical Systems Alternatives Haemonetics Alternatives ICU Medical Alternatives DENTSPLY SIRONA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANIK) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump Makes Major Crypto AnnouncementPay close attention to what I'm about to share… Most investors think Trump's pro-crypto policies will lift ...Crypto 101 Media | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredMarch 16th -- America’s most important day?50-Year Legend: Here's The Day Stocks Likely Crash Legendary quant analyst Marc Chaikin says in 50 years on...Chaikin Analytics | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anika Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anika Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
